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A crucial role for HVEM and BTLA
in preventing intestinal inflammation
Marcos W. Steinberg,1 Olga Turovskaya,1 Raziya B. Shaikh,1 Gisen Kim,1
Declan F. McCole,3 Klaus Pfeffer,4 Kenneth M. Murphy,5 Carl F. Ware,2
and Mitchell Kronenberg1
of Developmental Immunology and 2Division of Molecular Immunology, La Jolla Institute for Allergy
and Immunology, La Jolla, CA 92037
3Division of Gastroenterology, Department of Medicine, University of California San Diego, School of Medicine,
La Jolla, CA 92093
4Institute of Medical Microbiology, Heinrich-Heine-Universität Düsseldorf, D-40225 Düsseldorf, Germany
5Department of Pathology and Center for Immunology, and Howard Hughes Medical Institute, Washington University School
of Medicine, St. Louis, MO 63110

The interaction between the tumor necrosis factor (TNF) family member LIGHT and the TNF
family receptor herpes virus entry mediator (HVEM) co-stimulates T cells and promotes
inflammation. However, HVEM also triggers inhibitory signals by acting as a ligand that
binds to B and T lymphocyte attenuator (BTLA), an immunoglobulin super family member.
The contribution of HVEM interacting with these two binding partners in inflammatory
processes remains unknown. In this study, we investigated the role of HVEM in the development of colitis induced by the transfer of CD4+CD45RBhigh T cells into recombination activating gene (Rag)ⴚ/ⴚ mice. Although the absence of HVEM on the donor T cells led to a
slight decrease in pathogenesis, surprisingly, the absence of HVEM in the Ragⴚ/ⴚ recipients
led to the opposite effect, a dramatic acceleration of intestinal inflammation. Furthermore,
the critical role of HVEM in preventing colitis acceleration mainly involved HVEM expression by radioresistant cells in the Ragⴚ/ⴚ recipients interacting with BTLA. Our experiments emphasize the antiinflammatory role of HVEM and the importance of HVEM
expression by innate immune cells in preventing runaway inflammation in the intestine.
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Inflammatory bowel diseases (IBDs) comprise a
spectrum of immune-mediated conditions in
which the target organ is the intestine. IBD is
divided into two primary forms, Crohn’s disease and ulcerative colitis (1). Although the etiology remains unknown, increasing evidence
suggests that IBD is the result of a dysregulated
mucosal inflammatory response (2). TNF is a
particularly important contributor to intestinal
inflammation, and blockade of TNF with antiTNF antibodies is an effective treatment for a
subset of Crohn’s disease patients (3). Several
lines of evidence point to the TNF-related cytokine LIGHT (homologous to lymphotoxin,
shows inducible expression, and competes with
HSV glycoprotein D for herpes virus entry
mediator [HVEM], a receptor expressed by T
lymphocytes) as another important mediator of
mucosal inflammation and IBD pathogenesis
(4–6). Activated T cells and immature DCs exThe online version of this article contains supplemental material.
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press LIGHT, and it has been described as a
proinflammatory cytokine and a potent T cell
co-stimulatory molecule (7–10). Mature Th1type CD4+ T cells and mucosal T cells isolated
from patients with IBD express high levels of
LIGHT (4). Furthermore, transgenic mice with
T cells constitutively expressing LIGHT developed spontaneous multi-organ inflammation
that included the intestine (11, 12), and intestinal inflammation could be induced by transfer
of LIGHT transgenic T cells (13).
LIGHT signals via two members of the
TNF receptor super family, the lymphotoxin ␤
receptor, predominantly expressed by myeloid
lineage, stromal, and epithelial cells (14–17),
and the HVEM, broadly expressed by hematopoietic cells as well as by some somatic cells
(18–21). LIGHT-mediated IBD pathogenesis
in mice has been attributed to its interaction
with both of these receptors (6). Whereas the
interaction of LIGHT with lymphotoxin ␤ receptor is thought to induce transformations in
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RESULTS
The role of HVEM expression by T cells in colitis induction
To investigate the participation of HVEM in colitis pathogenesis, we used an experimental mouse model initiated by
1464

the adoptive transfer of CD4+CD45RBhigh naive T cells, depleted of CD25+ regulatory T cells, into syngeneic Rag⫺/⫺
mice. This leads to a progressive disease, with weight loss and
colitis appearing 5–10 wk after the transfer (33). To evaluate
if the expression of HVEM in T cells is required for colitis
induction, we transferred CD4+CD45RBhigh T cells isolated
from Hvem⫺/⫺ or WT mice into Rag⫺/⫺ recipients. As expected, WT donor CD4+CD45RBhigh T cells induced a
gradual weight loss in Rag⫺/⫺ recipients that correlated
with disease progression, as did the transfer of Hvem⫺/⫺
CD4+CD45RBhigh T cells (Fig. 1 A). Although at early time
points after the transfer weight loss in the Rag⫺/⫺ recipient mice
of Hvem⫺/⫺ T cells was slightly less pronounced, the recipients
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the gut mucosa that alter the normal microenvironment of
the intestine, its binding with HVEM expressed by T cells
promotes T cell activation and the T cell expansion required
for the full development of disease (6). In other contexts, engagement of HVEM by LIGHT delivers co-stimulatory signals leading to T cell activation (8, 9, 18, 22) and enhanced
T cell–mediated immunity (11, 12, 19, 23, 24). Furthermore,
it has been described that engagement of HVEM by LIGHT
induced activation of human mucosal T cells and increased
IFN-␥ release (4). Therefore, it appears that HVEM may
contribute to IBD pathogenesis by promoting T cell activation and Th1 responses (4, 6).
It has been recently discovered, however, that HVEM
can also deliver inhibitory signals to T cells (25, 26). These
inhibitory signals involve a receptor that binds HVEM, a
member of the Ig super family called B and T lymphocyte attenuator (BTLA) (25). Once engaged by HVEM, the ITIM
motifs in the cytoplasmic tail of BTLA become tyrosine
phosphorylated, allowing the recruitment of the phosphatases
SHP-1 and SHP-2 (27, 28). Recent studies have shown that
HVEM- as well as BTLA-deficient T cells are hyperresponsive to TCR-induced stimulation in vitro (26–28). Additionally, both HVEM- and BTLA-deficient mice presented a
higher susceptibility to experimental autoimmune encephalomyelitis (26, 28), whereas the loss of BTLA dramatically
accelerated partially MHC-mismatched cardiac allograft
rejection (29) and prolonged airway inflammation (30).
Furthermore, the BTLA–HVEM interaction limited T
cell activity in vivo, negatively regulating the homeostatic
expansion of a subset of CD8+ memory T cells (31). Despite its generally inhibitory role, BTLA has recently been
reported to play a role in promoting the survival of T cells
activated during a mouse model of graft versus host disease
(GVHD) (32).
Therefore, whereas some evidence indicates that HVEM
is the co-stimulatory receptor responsible for LIGHT-mediated T cell activation, other data demonstrate that HVEM
can be a negative regulator of T cell responses by triggering
BTLA-derived inhibitory signals. The actual contribution of
HVEM to T cell–mediated immune responses, and to the
pathogenesis of T cell–mediated inflammatory conditions
such as IBD, remains to be determined. Moreover, most of
the studies that investigate the role of HVEM binding to its
ligands have emphasized the expression of one or more of
these molecules by B and T lymphocytes, and their roles in
directly regulating lymphocyte responses. In this study, we
investigated the role of HVEM and its binding partners
in the development of colitis induced by the transfer of
CD4+CD45RBhigh T cells into Rag⫺/⫺ mice, and the possible
function of HVEM in cells of the innate immune system that
are present in the Rag⫺/⫺ hosts.

Figure 1. CD4+CD45RBhigh T cells do not require HVEM to induce
colitis. (A) Weight loss curves of Rag⫺/⫺ recipients transferred with
5 × 105 CD4+CD45RBhigh T cells isolated from either WT C57BL/6 mice
(open squares) or Hvem⫺/⫺ mice (filled squares). The graph shows the
average weight loss as a percentage of the initial weight of four mice in
each group, and they are representative of four independent experiments.
(B) H&E staining of proximal and distal colon of Rag⫺/⫺ mice transferred
with WT or Hvem⫺/⫺ T cells. The histological scores of the representative
sections shown are indicated (bottom right of each panel). GC, goblet
cells. (C) Average scores of the proximal and distal colon sections were
evaluated 12 wk after the transfer of T cells. Sections of the large intestine isolated from different recipients were microscopically analyzed as
described in Materials and methods. Each square represents a single
mouse (eight per group). *, P < 0.05.
HVEM–BTLA INTERACTION PREVENTS INTESTINAL INFLAMMATION | Steinberg et al.
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Accelerated colitis in Hvemⴚ/ⴚRagⴚ/ⴚ recipients
HVEM expression is not restricted to T cells, and therefore
to evaluate if HVEM expressed by non–T cells participates
in colitis pathogenesis, we bred HVEM-deficient Rag⫺/⫺
(Hvem⫺/⫺Rag⫺/⫺) animals to use as recipients. Hvem⫺/⫺Rag⫺/⫺
recipients that were transferred with WT CD4+CD45RBhigh
T cells exhibited a surprising acceleration of weight loss and
colitis, as determined by the presence of diarrhea and other
clinical signs, such as reduced mobility and piloerection of
the fur. Notably, recipient Hvem⫺/⫺Rag⫺/⫺ mice showed a
reduction of ⵑ20% of their initial starting weight only 2 wk
after transfer (Fig. 2 A). The intestinal inflammation in these
recipients was progressive and lethal, and in most cases the
recipients did not survive beyond 3–4 wk after transfer. This
accelerated inflammation was confined, however, predominantly to the large intestine (not depicted). Conversely, in
the same brief period, Rag⫺/⫺ recipients did not show any
weight loss (Fig. 2 A). In addition to the faster weight loss,
transferred Hvem⫺/⫺Rag⫺/⫺ mice presented early evidence of

Figure 2. Colitis acceleration in Hvemⴚ/ⴚRagⴚ/ⴚ mice. Transfer of CD4+CD45RBhigh T cells into Hvem⫺/⫺Rag⫺/⫺ mice dramatically accelerated colitis.
(A) Weight loss curves of Rag⫺/⫺ (squares) and Hvem⫺/⫺Rag⫺/⫺ (circles) recipients of 5 × 105 WT T cells showed an extremely rapid disease progression in
Hvem⫺/⫺Rag⫺/⫺ animals. Data correspond to the average of five mice per group and are representative of five independent experiments. (B) H&E staining
of proximal and distal colon sections are shown. (C) Average scores of the proximal and distal colon sections from individual mice were evaluated 2 wk
after the transfer of T cells. Each symbol represents an individual mouse (n = 5), and representative data from four experiments are shown. **, P < 0.005.
(D) Weight loss comparison after transfer of WT (open circles) or Hvem⫺/⫺ (filled circles) CD4+CD45RBhigh T cells into Hvem⫺/⫺Rag⫺/⫺ recipients (n = 6–7).
(E) Combined proximal and distal histological analysis of colon sections performed 2 wk after the transfers described in part D. Each symbol represents an
individual mouse (n = 7).
JEM VOL. 205, June 9, 2008
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unquestionably became ill, eventually all the transferred
Rag⫺/⫺ recipients showed an equivalent weight loss (Fig. 1 A),
and the overall difference between Hvem⫺/⫺ and WT donor
T cells did not reach statistical significance. Microscopic analysis of hematoxylin and eosin (H&E)-stained tissue sections
obtained from the large intestine of transferred mice revealed
severe inflammation in all of the recipients. However, mice
transferred with Hvem⫺/⫺ T cells had lower mononuclear cell
infiltrates in the proximal and distal colon. In addition, these
recipients had a higher number of goblet cells in the distal
colon, indicating that inflammation in these animals was
milder (Fig. 1 B). Scoring of sections obtained from the
recipients transferred with Hvem⫺/⫺ T cells showed a lower
average histological score than in the animals that received
WT T cells (Fig. 1 C). Overall, these results suggest that
HVEM expression on donor T cells contributed to a limited
extent to increasing intestinal inflammation; however, HVEM
expression in T cells was not absolutely required for colitis development.
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Rapid accumulation of T cells in the large intestine
of Hvemⴚ/ⴚRagⴚ/ⴚ recipients
To characterize the colitis acceleration observed in Hvem⫺/⫺
Rag⫺/⫺ mice, we investigated the fate of the transferred T
cells. We determined the number of CD4+ T lymphocytes in
the spleens and mesenteric lymph nodes (MLNs) of transferred mice, two sites where T cells expand dramatically after
transfer to immune-deficient hosts (34, 35). 1 wk after transfer, the number of CD4+ T cells in the MLNs of Hvem⫺/⫺
Rag⫺/⫺ animals was approximately threefold higher than in
Rag⫺/⫺ mice (Fig. 3 A). This difference was highly significant
(P = 0.005). The number of T cells in the spleens of Hvem⫺/⫺
Rag⫺/⫺ mice was also slightly higher than in Rag⫺/⫺ recipients, although not statistically significant (Fig. 3 A). Elevated
numbers of T cells in the MLNs of Hvem⫺/⫺Rag⫺/⫺ animals
were only observed at early time points after the transfer, and
by 2 wk after transfer, the number of CD4+ TCR-␤+ lymphocytes in the MLNs was essentially equivalent in both recipients (Fig. 3 B). To investigate if the early accumulation of
transferred T cells in inductive sites such as MLNs in the
Hvem⫺/⫺Rag⫺/⫺ mice also affected the target organ, we assessed the accumulation of CD4+ TCR-␤+ T cells in the
large intestine of the recipients. As early as 7 d after transfer,
T lymphocytes were detectable in the large intestine. At this
time, the average number of CD4+ TCR-␤+ cells infiltrating
the epithelium of the Hvem⫺/⫺Rag⫺/⫺ mice was 2.3-fold
higher than in Rag⫺/⫺ mice (Fig. 3 A). However, by 2 wk af1466

ter transfer, intraepithelial CD4+ TCR-␤+ cell numbers in
Hvem⫺/⫺Rag⫺/⫺ mice were 10-fold higher (P < 0.005) (Fig.
3 B). Accordingly, the number of CD4+ TCR-␤+ lamina
propria lymphocytes (LPLs) was also significantly higher in
Hvem⫺/⫺Rag⫺/⫺ recipients at 2 wk (Fig. 3 B). Collectively,
these results demonstrate that the absence of HVEM in the
Rag⫺/⫺ mice led to a more rapid accumulation of transferred
T cells in the MLNs and large intestine.
Increased T cell cytokine production
in Hvemⴚ/ⴚRagⴚ/ⴚ recipients
To further characterize the colitis acceleration observed in
Hvem⫺/⫺Rag⫺/⫺ mice, we investigated the profile of cytokines produced in the large intestine of the recipient animals.
2 wk after transfer, total mRNA was purified from the colon
and subjected to RT-PCR analysis for several cytokines.
RT-PCR revealed the presence of TNF and IFN-␥ mRNAs,
and lower levels of IL-17 mRNA (Fig. 3 C). Notably, the
amount of mRNA for these cytokines, and in particular
for TNF, was considerably higher in samples isolated from
Hvem⫺/⫺Rag⫺/⫺ mice (Fig. 3 C). The higher level of proinflammatory cytokines in the intestine of Hvem⫺/⫺Rag⫺/⫺
animals correlated with the rapid and severe intestinal inflammation observed. It should be noted that increased mRNA
for TGF-␤ and IL-10 in the Hvem⫺/⫺Rag⫺/⫺ mice was also
observed when compared with Rag⫺/⫺ recipients. The increased presence of these antiinflammatory cytokine mRNAs
in the Hvem⫺/⫺Rag⫺/⫺ recipients could reflect a compensatory regulatory mechanism in the face of inflammation, although the amount of IL-10 mRNA was very low in all the
samples (Fig. 3 D). The amount of mRNA for IL-12 family
cytokines in the colon was not very great, but in accord with
the higher levels of IFN-␥ mRNA observed in Hvem⫺/⫺Rag⫺/⫺
mice, we also detected an increase in IL-12 mRNA in the
colon of these animals (Fig. 3 E). The level of mRNA for IL-23,
however, was equivalent in both Rag⫺/⫺ and Hvem⫺/⫺Rag⫺/⫺
mice (Fig. 3 E).
To determine if the transferred T cells had the capacity
to produce proinflammatory cytokines in the colon of the
Hvem⫺/⫺Rag⫺/⫺ recipient mice, we evaluated cytokine production by donor-derived LPLs restimulated in vitro. LPLs
were purified from the large intestine of Rag⫺/⫺ or Hvem⫺/⫺
Rag⫺/⫺ recipient mice, stimulated with PMA, and ionomycin, and 48 h later cytokines were determined by ELISA.
The amounts of IFN-␥, TNF, and IL-2 in the culture supernatants of cells obtained from Hvem⫺/⫺Rag⫺/⫺ mice were
considerably higher than those secreted by cells isolated from
Rag⫺/⫺ recipients (Fig. 3 F). Rather than an increased capacity
to produce cytokines, the higher amounts of cytokines in the
cultures of cells isolated from Hvem⫺/⫺Rag⫺/⫺ mice could have
been due to the increased number of T cells in the LPL preparations. Indeed, the percentage of CD4+ TCR-␤+ within
the LPL suspension isolated from Hvem⫺/⫺Rag⫺/⫺ mice was
about twofold higher than that observed in Rag⫺/⫺ animals
(not depicted). The increment in cytokines in the isolated LPLs
from Hvem⫺/⫺Rag⫺/⫺ mice was increased more than twofold,
HVEM–BTLA INTERACTION PREVENTS INTESTINAL INFLAMMATION | Steinberg et al.
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severe intestinal inflammation. Examination of H&E-stained
sections obtained from Hvem⫺/⫺Rag⫺/⫺ recipients revealed
prominent epithelial cell hyperplasia, absence of goblet cells,
and a massive infiltration of mononuclear cells in the colons
of these animals (Fig. 2 B). Histological analysis performed on
samples isolated from large intestine of these recipients 2 wk
after transfer had an average pathology score of 8.8 ± 2.2 out
of a possible of 14 (Fig. 2 C). Samples from Rag⫺/⫺ recipients
at the same early time after transfer showed almost intact epithelial crypts with absence of epithelial cell hyperplasia and
only few mononuclear cell infiltrates (Fig. 2 B). The average
score for samples obtained from the transferred Rag⫺/⫺ mice
at this time was only 0.8 ± 1.0 (Fig. 2 C).
We transferred Hvem⫺/⫺ donor T cells into Hvem⫺/⫺Rag⫺/⫺
mice to analyze the situation in which HVEM is entirely missing. Interestingly, induced colitis and wasting disease in the
completely HVEM-deficient situation were still accelerated
compared with transfers to Rag⫺/⫺ animals. Weight loss in
Hvem⫺/⫺Rag⫺/⫺ mice transferred with HVEM-deficient T
cells was equally accelerated compared with the same recipients transferred with WT T cells (Fig. 2 D). Histological scores
in these recipients completely lacking HVEM were also equivalent to those observed in Hvem⫺/⫺Rag⫺/⫺ animals transferred
with WT T cells (Fig. 2 E). Overall, these results demonstrate
that the absence of HVEM expression in Rag⫺/⫺ host cells led
to a dramatic acceleration of colitis, and they show that this
dramatic effect was dominant over any deceleration of disease
caused by the absence of HVEM expression by donor T cells.
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however, suggesting that increased proinflammatory cytokines
in the LPLs of these recipients could be due to a combination of increased cell number and increased effectors. Collectively, these findings suggest that the presence of increased
CD4+ T cells secreting high amounts of proinflammatory cytokines in the intestine of Hvem⫺/⫺Rag⫺/⫺ recipients contributed to the more rapid development of colitis.
DCs were not greatly affected in Hvemⴚ/ⴚ mice
Previous reports have suggested a role for HVEM in DC
maturation and cytokine production (36, 37), and therefore
the absence of HVEM expression on DCs in the Rag⫺/⫺ recipients might cause an abnormal development and/or function of these cells. In WT or Hvem⫺/⫺ mice, however, the
percentage of DCs in the spleens and MLNs was essentially
equivalent, and the two major subsets of DCs, those expressing high levels of CD11c and CD8␣, and those expressing
CD11b, were similarly represented in the MLNs of WT and
Hvem⫺/⫺ animals (Fig. S1 A, available at http://www.jem
.org/cgi/content/full/jem.20071160/DC1, and not depicted).
JEM VOL. 205, June 9, 2008

CD11c+ cells freshly isolated from the MLNs of the two
types of mice expressed equivalent levels of the co-stimulatory molecules CD86 and CD80, suggesting that the DC
maturation state was not greatly affected by the absence of
HVEM (Fig. S1 A). To determine if the threshold for stimulation for DCs is altered in the absence of HVEM, CD11c+
cells from MLNs were stimulated with LPS. Upon stimulation, both WT and Hvem⫺/⫺ DCs expressed similar levels of
CD40 and CD86 (Fig. S1 B). Moreover, after LPS stimulation, the percentage of WT and Hvem⫺/⫺ MLN DCs expressing IL-12 was essentially equivalent (Fig. S1 B). Collectively,
these results demonstrate that the absence of HVEM in DCs
did not significantly affect their percentage, maturation state,
or their capacity to secrete cytokines. For priming naive CD4+
T cells, freshly isolated DCs from the MLNs of Hvem⫺/⫺
mice were slightly more effective than their WT counterparts (proliferation indices of 2.6 and 2.1, respectively),
although splenic DCs from these mice were not different
from WT mice (Fig. S1 C). Likewise MLN DCs from mice
deficient for the HVEM ligand BTLA did not prime more
1467
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Figure 3. Increased T cells and cytokines in Hvemⴚ/ⴚRagⴚ/ⴚ recipients. The number of CD4+ TCR-␤+ cells in the spleens, MLNs, and large intestines
of recipient mice was assessed at the indicated times. (A) 1 wk after transfer, Rag⫺/⫺ (squares) and Hvem⫺/⫺Rag⫺/⫺ (circles) mice, four in each group,
were analyzed by flow cytometry for T cells in the spleens, large IELs, and MLNs. (B) Shows same as in A, but including LPLs and analyzed 2 wk after transfer. Each symbol represents an individual mouse with a total of 7–10 mice per group. *, P < 0.05; **, P < 0.005. (C–E) Real-time PCR performed on tissue
samples isolated from the large intestines of individual Rag⫺/⫺ (filled bars) or Hvem⫺/⫺Rag⫺/⫺ (open bars) recipients 2 wk after transfer. Error bars represent SD of triplicate measurements. (F) LPLs isolated from transferred Hvem⫺/⫺Rag⫺/⫺ (open bars) and Rag⫺/⫺ (filled bars) recipients at 2 wk were stimulated ex vivo with PMA and ionomycin. After 48 h, cytokines in the supernatant were measured by ELISA.
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effectively (Fig. S1 C). In summary, HVEM deficiency did
not grossly alter DCs, and the small increase in proliferation
of naive T cells stimulated with Hvem⫺/⫺ DCs from MLNs is
unlikely to account by itself for the accelerated T cell expansion and colitis pathogenesis in Hvem⫺/⫺ recipients.

Figure 4. HVEM expression by radioresistant Ragⴚ/ⴚ cells prevents colitis acceleration. (A) Experimental design. Lethally irradiated
Hvem⫺/⫺Rag⫺/⫺ mice were transplanted with Rag⫺/⫺ BM cells to generate Rag⫺/⫺→Hvem⫺/⫺Rag⫺/⫺ chimeric mice. Reciprocal Hvem⫺/⫺Rag⫺/⫺→Rag⫺/⫺
chimeras also were generated. 10 wk after transplant, chimeric mice were used as recipients of CD4+CD45RBhigh T cells. (B) Analysis of reconstitution. HVEM
expression in peripheral blood cells of the chimeric animals was assessed 8 wk after BM cell transplant by flow cytometry analysis for HVEM expression
by CD45+ cells. Open histograms represent HVEM staining, and filled histograms represent the isotype control. Representative data are shown from one
of many similar analyses of blood cells and cells from immune organs. (C) Transfer of 5 × 105 CD4+CD45RBhigh T cells into Hvem⫺/⫺Rag⫺/⫺→Rag⫺/⫺
(squares) and Rag⫺/⫺→Hvem⫺/⫺Rag⫺/⫺ (gray circles) chimeric recipients. Weight loss curves correspond to the average of six to eight chimeric mice per
group. (D) Histological scores were determined 2 wk after transfer. Each symbol represents a single mouse of a total of seven Hvem⫺/⫺Rag⫺/⫺→Rag⫺/⫺
(squares) and eight Rag⫺/⫺→Hvem⫺/⫺Rag⫺/⫺ (circles) chimeric mice. **, P < 0.005. Data shown are representative from one of two independent experiments.
1468
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HVEM expression in radioresistant cells is required
to prevent colitis acceleration
Because there was not an obvious APC defect in the Hvem⫺/⫺
mice, to begin to identify the critical cell type(s) that must
express HVEM, we analyzed chimeric Rag⫺/⫺ recipient mice
that expressed HVEM only in irradiation-resistant cells, or
only in cells derived from BM progenitors. To construct the
chimeras, after lethal irradiation, Hvem⫺/⫺Rag⫺/⫺ mice were
reconstituted with Rag⫺/⫺ BM cells (Rag⫺/⫺→Hvem⫺/⫺Rag⫺/⫺),
and reciprocal chimeras were constructed in Rag⫺/⫺ mice

given Hvem⫺/⫺Rag⫺/⫺ BM cells (Hvem⫺/⫺Rag⫺/⫺→Rag⫺/⫺)
(Fig. 4 A). To verify that the chimeric mice were properly
reconstituted, 8 wk after BM transplantation HVEM expression in peripheral blood cells from these animals was
monitored. As expected, blood cells isolated from Hvem⫺/⫺
Rag⫺/⫺→Rag⫺/⫺ mice expressing the hematopoietic lineage
marker CD45 did not have detectable surface HVEM, indicating reconstitution by the Hvem⫺/⫺ donor BM cells (Fig. 4 B).
In contrast, in Rag⫺/⫺→Hvem⫺/⫺Rag⫺/⫺ chimeric mice the
vast majority of the hematopoietic cells expressed intermediate or high levels of HVEM, indicating that they derived
from the Hvem+/+ donors (Fig. 4 B). A similar degree of reconstitution was observed when organs containing immune
cells from the chimeras were analyzed (not depicted).
Surprisingly, the transfer of CD4+CD45RBhigh T cells
into Rag⫺/⫺→Hvem⫺/⫺Rag⫺/⫺ chimeric recipients induced a
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Rag⫺/⫺ animals and accelerated development of disease. We
therefore performed transfer experiments using Light⫺/⫺ donor T cells. The results showed similar weight loss in Rag⫺/⫺
mice transferred with either Light⫺/⫺ or WT CD4+CD45RBhigh
T cells (Fig. 5 A). However, histological analysis performed
in samples obtained from the large intestine of Rag⫺/⫺ recipients 12 wk after the transfer revealed lower levels of inflammation in animals transferred with Light⫺/⫺ T cells (Fig. 5 B).
This is consistent with other data indicating that LIGHT is a
co-stimulatory molecule for T lymphocytes. Because the
outcome after transfer of Light⫺/⫺ T cells was opposite to the
results after transfer to Hvem⫺/⫺Rag⫺/⫺ recipients, we conclude that the accelerating effects of host HVEM deficiency
were not due to the absence of interactions with LIGHT expressed by the donor T cells.
Importantly, the transfer of Light⫺/⫺ CD4+CD45RBhigh
T cells into Hvem⫺/⫺Rag⫺/⫺ recipients induced a dramatic
acceleration of weight loss (Fig. 5 C) and colitis progression
assessed by the presence of diarrhea and other clinical signs. The
disease acceleration was similar to that observed in Hvem⫺/⫺
Rag⫺/⫺ mice transferred with WT T cells. Furthermore, the
histological scores obtained with samples isolated from these
Hvem⫺/⫺Rag⫺/⫺ animals 2 wk after the transfer showed
equivalent levels of intestinal inflammation, regardless of the
presence of LIGHT expression by the donor T cells (Fig. 5 D).

Effects of HVEM ligand expression by T cells
An appealing hypothesis for explaining the accelerated colitis
in Hvem⫺/⫺Rag⫺/⫺ recipients is that enhanced disease is caused
by the absence of an interaction between HVEM expressed
by a cell type in the Rag⫺/⫺ recipients with an HVEM binding
partner expressed by the donor T cells. Recent publications
have suggested that expression of LIGHT by T cells is able to
regulate innate immune responses by interacting with the
HVEM receptor (36, 38–41). Therefore, the absence of interactions between T cell–derived LIGHT and HVEM on host
cells might lead to a dysregulated innate immune response in

Figure 5. Lightⴚ/ⴚ T cells do not cause accelerated colitis. (A) Weight
loss curves of Rag⫺/⫺ recipients transferred with either WT (open squares)
or Light⫺/⫺ CD4+CD45RBhigh T cells (open diamonds). The graph shows the
average of four mice per group and is representative of one of three independent experiments. (B) Average histological scores were evaluated
12 wk after T cell transfer. Each square represents a single mouse of a
total of six to seven mice in each group. *, P < 0.05. (C) Results from the
transfer of either WT (open circles) or Light⫺/⫺ (filled circles) T cells into
Hvem⫺/⫺Rag⫺/⫺ mice. Data shown correspond to the average weight loss
of six mice per group. (D) Average histological scores analyzed 2 wk after
WT or Light⫺/⫺ CD4+CD45RBhigh T cell transfer to Hvem⫺/⫺Rag⫺/⫺ animals.
Each circle represents a single mouse in a total of six mice per group.
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rapidly developing disease (Fig. 4 C). Similar to the intact
Hvem⫺/⫺Rag⫺/⫺ mice, Rag⫺/⫺→Hvem⫺/⫺Rag⫺/⫺ recipients
lost >20% of their initial weight by 2 wk after T cell transfer.
Conversely, Hvem⫺/⫺Rag⫺/⫺→Rag⫺/⫺ chimeric recipients
that received CD4+CD45RBhigh T lymphocytes did not lose
body weight in the same period of time (Fig. 4 C). Consistent with the difference in weight loss, histological scoring
performed in large intestine samples collected from the transferred chimeric recipients revealed a more severe inflammation and tissue damage in Rag⫺/⫺→Hvem⫺/⫺Rag⫺/⫺ mice
than in the Hvem⫺/⫺Rag⫺/⫺→Rag⫺/⫺ recipients (average
score = 10.4 ± 2.0 in Rag⫺/⫺→Hvem⫺/⫺Rag⫺/⫺ animals as
opposed to 0.3 ± 0.5 in Hvem⫺/⫺Rag⫺/⫺→Rag⫺/⫺ mice)
(Fig. 4 D). These results indicate that HVEM prevents colitis
acceleration principally when expressed by radioresistant cells
in the Rag⫺/⫺ hosts.
A radiation-resistant cell that might prevent accelerated
inflammation through HVEM expression is the intestinal epithelial cell (IEC). In fact, human epithelial carcinoma cell
lines (not depicted) and freshly isolated mouse colonic epithelial cells express HVEM (Fig. S2 A, available at http://
www.jem.org/cgi/content/full/jem.20071160/DC1). A feature of IBD, in particular Crohn’s disease, is increased intestinal permeability arising from a defect in the intestinal
epithelium. Permeability to D-[1-14C]-mannitol therefore was
measured across tissues from proximal and distal large intestine, as well as the cecum, which were stripped of underlying
smooth muscle and mounted in Ussing chambers. Although
the trend was toward increased permeability in the distal colon
of Hvem⫺/⫺ mice, the difference was not significant when
compared with WT tissues. However, permeability in the
distal colon of both WT and Hvem⫺/⫺ mice was significantly
lower than that observed in inflamed tissues isolated from
WT mice with colitis that had been induced by dextran sodium sulfate (DSS) (Fig. S2 B). Similar to the results from the
distal large intestine, permeability in the proximal colon and
cecum of WT and Hvem⫺/⫺ animals was essentially equivalent (not depicted). Therefore, epithelial permeability is not
compromised under noninflammatory conditions in the absence of HVEM expression. Colitis induced by DSS represents a well-established epithelial injury model of intestinal
inflammation. Hvem⫺/⫺ mice also displayed no increase in
susceptibility to DSS-induced colitis when compared with
WT mice (Fig. S3, A and B).
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Figure 6. Minimal effect of T cell BTLA deficiency on colitis
pathogenesis. (A) BTLA expression on freshly isolated naive CD4+ T cells
and by CD4+ T cells stimulated in vitro with an anti-CD3 mAb in the
presence of irradiated T cell–depleted splenocytes. (B) BTLA expression on
transferred CD4+ T cells isolated from Hvem⫺/⫺Rag⫺/⫺ recipients 2 wk
after transfer. Histograms represent BTLA expression by gated CD4+ TCR␤+ cells from the indicated sites. (C) Transfer of Btla⫺/⫺ CD4+CD45RBhigh
T cells into Rag⫺/⫺ recipients. Weight loss curves of Rag⫺/⫺ recipients
transferred with either WT T cells (squares) or Btla⫺/⫺ T cells (triangles).
Data shown represent the average of six to eight mice in each group.
(D) Histological scores were evaluated 2 (left) or 5 wk (right) after the
transfer of T cells. Each symbol represents an individual mouse (n = 5–8).
Data are representative of four independent experiments. *, P < 0.05.
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also reduced (mean fluorescence intensity = 7,456 for LPL vs.
mean fluorescence intensity = 26,183 for MLNs). Surprisingly, although BTLA is an inhibitory receptor, Btla⫺/⫺ T cells
transferred into Rag⫺/⫺ animals induced colitis similar to WT
donors when weight loss was measured (Fig. 6 C). Histological analysis performed 2 wk after transfer revealed higher average scores for recipients transferred with Btla⫺/⫺ T cells, but
there was no difference at 5 wk (Fig. 6 D).
Reduced number of BTLA-deficient T cells
in Ragⴚ/ⴚ recipients
It has been recently shown that BTLA plays a role in the survival of T cells activated in a mouse GVHD model (32). In
light of our finding that Rag⫺/⫺ recipients of BTLA-deficient
T cells did not develop accelerated colitis, we hypothesized
that BTLA-deficient T cells transferred into Rag⫺/⫺ recipients
might have a survival defect, leading to a reduced number of
effector T cells that ultimately might affect the onset of colitis.
To address this possibility, we performed cotransfers of equal
numbers of WT CD45.1+ congenic and Btla⫺/⫺ CD45.2+
CD4+CD45RBhigh T cells into Rag⫺/⫺ recipients. Btla⫺/⫺ T
cells did not accumulate as much as WT cells. The percentages (Fig. 7 A) and absolute numbers (Fig. 7 B) of CD45.1+
CD4+ TCR-␤+ cells in the spleens, MLNs, LPLs, and intestinal epithelial lymphocytes (IELs) were considerably higher
than those for Btla⫺/⫺ (CD45.1⫺) T cells 2 wk after transfer.
Although the Btla⫺/⫺ T cells did not accumulate as much as
WT donors, the BTLA-deficient T cells in Rag⫺/⫺ mice were
capable of secreting proinflammatory cytokines to a similar
extent (Fig. 7 C). Based on these findings, we hypothesize
that transfer of Btla⫺/⫺ T cells did not recapitulate the results
in Hvem⫺/⫺Rag⫺/⫺ recipients in part because the lower numbers of effector T cells prevented disease acceleration.
Signaling through BTLA prevented colitis acceleration
To further explore the role of the BTLA inhibitory receptor, we evaluated colitis development in recipient Hvem⫺/⫺
Rag⫺/⫺ mice treated with an anti-BTLA mAb (clone 6F7).
When added to T cell–APC co-cultures stimulated with an
anti-CD3 antibody, the 6F7 antibody attenuated T cell responses. The expression of CD25 and the production of IL-2
by anti-BTLA–treated T cells were reduced compared with
the IgG-treated control (Fig. S4, available at http://www
.jem.org/cgi/content/full/jem.20071160/DC1). Importantly,
the inhibitory effect on immune responses mediated by the
6F7 antibody was specific to BTLA-expressing T cells, as the
activation and proliferation of Btla⫺/⫺ T cells was essentially
equivalent in cultures treated with the 6F7 mAb or an irrelevant
IgG control (Fig. S4 B). The anti-BTLA mAb reduced IL-2
and CD25 induction even when Hvem⫺/⫺ T cells and APCs
were co-cultured (Fig. S4 D), indicating that the mAb acts directly by engaging BTLA, as opposed to blocking interactions
with HVEM. These results indicate that the anti-BTLA mAb
6F7 has agonistic activity that stimulates BTLA-mediated inhibitory signals leading to decreased T cell–immune responses
in vitro.
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Therefore, rapid colitis induction in the absence of HVEM
expression is dominant over the decreased inflammation observed when Light⫺/⫺ T cells were transferred.
The inhibitory HVEM ligand BTLA is expressed by activated T cells, and therefore interactions between Rag⫺/⫺ host
HVEM and T cell BTLA could alter the acceleration of colitis.
To test this, we evaluated BTLA expression by naive CD4+ T
cells and by CD4+ T cells after transfer. Consistent with previous reports (42), we detected BTLA expression on naive and
activated CD4+ T lymphocytes. In vitro TCR stimulation enhanced BTLA expression on CD4+ T cells, with the highest
level of BTLA observed 2–3 d after stimulation (Fig. 6 A).
Likewise, we found BTLA expression on CD4+ T cells isolated from the spleens, MLNs, and LPLs of transferred Rag⫺/⫺
recipients (Fig. 6 B). Although BTLA expression on LPLs was
slightly lower than that observed on T cells from the spleens or
MLNs, this was likely a consequence of the reduced surface
protein expression caused by the collagenase digestion during
LPL isolation. Consistent with this, the amount of CD4 was
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Figure 7. Reduced accumulation of Btlaⴚ/ⴚ T cells in Ragⴚ/ⴚ
recipients. Co-transfer of congenic CD45.1+ and CD45.2+ Btla⫺/⫺
CD4+CD45RBhigh T cells into Rag⫺/⫺ recipients. (A) Representative percentages of CD45.1+ (Btla+/+) and CD45.1⫺ (Btla⫺/⫺) CD4+ TCR-␤+ cells
in the spleens, MLNs, LPLs, and IELs of Rag⫺/⫺ mice analyzed 2 wk after
T cell transfer. (B) Same as A, but showing absolute numbers of
CD45.1+ (squares) and CD45.1⫺ (circles) CD4+TCR-␤+ T cells. Each symbol
represents an individual mouse (n = 4). *, P < 0.05. (C) Intracellular
IFN-␥ staining of CD4+TCR-␤+ CD45.1+ (top dot plots) and CD45.1⫺
(bottom dot plots) T cells isolated from Rag⫺/⫺ mice and restimulated ex
vivo with PMA and ionomycin. Data shown correspond to a single mouse
in a total of four mice per group and are representative of two independent experiments.
JEM VOL. 205, June 9, 2008

all the transferred animals presented with severe intestinal inflammation and similar histological average scores (Fig. 8 D).
These results demonstrate that the anti-BTLA mAb prevents
colitis acceleration when the donor T cells express BTLA.
Therefore, we conclude that BTLA signaling on T cells mediated by HVEM expressed by an irradiation-resistant cell is
crucial to prevent colitis acceleration.
Accelerated colitis in Btlaⴚ/ⴚRagⴚ/ⴚ recipients
Although the effect of the agonistic anti-BTLA mAb required
BTLA expression by T cells, the experiments presented above
prove only that T cell expression of BTLA is necessary, but
not sufficient, and therefore it remained possible that BTLA
expression by host cells in the Rag⫺/⫺ mice may also be required for preventing colitis acceleration. To investigate this
possibility, we used Btla⫺/⫺Rag⫺/⫺ animals as recipients of
WT CD4+CD45RBhigh T cells. The transfer of T cells into
Btla⫺/⫺Rag⫺/⫺ recipients led to faster weight loss (Fig. 9 A).
Furthermore, histological analysis performed 2 wk after the
transfer on samples isolated from the large intestine revealed a
more severe intestinal inflammation in Btla⫺/⫺Rag⫺/⫺ mice
(Fig. 9 B). To determine if disease acceleration in Btla⫺/⫺Rag⫺/⫺
mice was comparable to that observed in HVEM-deficient

Figure 8. Signaling through BTLA prevents colitis acceleration
in Hvemⴚ/ⴚRagⴚ/ⴚ recipients. (A) Weight loss curves of Hvem⫺/⫺Rag⫺/⫺
mouse recipients of WT T cells treated with either 100 μg anti-BTLA mAb
(clone 6F7) or IgG1 isotype control twice a week beginning at the time of
T cell transfer. Data shown represent the average of four mice in each
group and are representative of two independent experiments. (B) Histological scoring performed 3 wk after T cell transfer revealed milder intestinal inflammation in samples obtained from Hvem⫺/⫺Rag⫺/⫺ animals
treated with the anti-BTLA mAb. Each circle represents a single mouse in
a total of eight mice per group. *, P < 0.05. (C) Same as A, except that
Hvem⫺/⫺Rag⫺/⫺ animals were transferred with Btla⫺/⫺ CD4+CD45RBhigh
T cells. (D) Histological analysis 3 wk after transfer revealed equivalent
intestinal inflammation in all transferred Hvem⫺/⫺Rag⫺/⫺ animals regardless of the treatment with the anti-BTLA mAb. Each circle represents a
single mouse in a total of five mice per group.
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We found that the anti-BTLA mAb also has agonistic activity in vivo. Injection of the anti-BTLA mAb every 3 d beginning at the time of T cell transfer greatly delayed weight
loss and disease progression (Fig. 8 A). Furthermore, Hvem⫺/⫺
Rag⫺/⫺ recipients treated with the anti-BTLA mAb had
lower average histological scores (Fig. 8 B). Collectively, these
results demonstrate that BTLA engagement was required
to prevent colitis acceleration, and they suggest that the rapid
development of disease in Hvem⫺/⫺Rag⫺/⫺ mice is likely to
be caused by the absence of BTLA signaling.
To evaluate if the anti-BTLA mAb prevents colitis by acting on donor T cells, we transferred Btla⫺/⫺ CD4+CD45RBhigh
T cells into Hvem⫺/⫺Rag⫺/⫺ recipients that were then treated
with the anti-BTLA mAb. Hvem⫺/⫺Rag⫺/⫺ mice transferred
with Btla⫺/⫺ T cells showed faster weight loss regardless of
treatment with the anti-BTLA mAb (Fig. 8 C). In addition,
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hosts, WT CD4+CD45RBhigh were simultaneously transferred
into Btla⫺/⫺Rag⫺/⫺ or Hvem⫺/⫺Rag⫺/⫺ mice. In the two
groups of recipients, colitis development was essentially
equivalent. Although the trend was toward slightly less weight
loss and less severe histological scores in Btla⫺/⫺Rag⫺/⫺ mice
than in Hvem⫺/⫺Rag⫺/⫺ mice, the difference did not reach
statistical significance (Fig. 9, C and D). Similar results were
obtained when Btla⫺/⫺Rag⫺/⫺ recipients were transferred with
Btla⫺/⫺ CD4+CD45RBhigh, a situation where BTLA was
absent in both donor and host cells (Fig. 9, C and D). Collectively, these results demonstrate that BTLA expression by
Rag⫺/⫺ host cells also prevents accelerated colitis in the T cell
transfer model.

Figure 9. Accelerated colitis in Btlaⴚ/ⴚRagⴚ/ⴚ recipients. (A) Weight
loss curves of Rag⫺/⫺ (squares) and Btla⫺/⫺Rag⫺/⫺ (triangles) recipients
transferred with 5 × 105 WT T cells. Data correspond to the average of
four to six mice per group. (B) Combined proximal and distal colon histological scores were evaluated 2 wk after T cell transfer. Each symbol
represents an individual mouse from a total of six to seven animals
per group. (C) Weight loss curves of Hvem⫺/⫺Rag⫺/⫺ (circles) and
Btla⫺/⫺Rag⫺/⫺ (open triangles) recipients transferred with 5 × 105 WT
T cells, and Btla⫺/⫺Rag⫺/⫺ mice transferred with 5 × 105 Btla⫺/⫺ T cells
(filled triangles). Data correspond to the average of four to six mice per
group and are representative of two independent experiments. (D) Histological scores performed on samples obtained from two independent
experiments 2 wk after T cell transfer. Each symbol represents an individual mouse from a total of 5–11 animals per group. *, P < 0.05.
1472

HVEM–BTLA INTERACTION PREVENTS INTESTINAL INFLAMMATION | Steinberg et al.

Downloaded from jem.rupress.org on September 13, 2011

DISCUSSION
HVEM is a unique TNF family receptor because it has the ability both to transmit positive signals and to induce negative
signals. Subsets of T cells constitutively express HVEM, and
therefore it is perhaps not surprising that many of the experiments analyzing the role of HVEM have focused on T lymphocytes. HVEM expressed by T cells is a co-stimulatory receptor
for LIGHT-mediated T cell activation (8, 9, 18, 22, 25).
Furthermore, recent reports demonstrated that HVEM also
engages BTLA and inhibits T cell proliferation (25, 26, 43).

Hvem⫺/⫺ mice do not have a dramatic phenotype, however,
which might reflect the balance between the activating and inhibitory signals mediated by HVEM.
In this report, we analyzed the role of HVEM in intestinal
inflammation induced by the transfer of naive CD4+ T cells
into Rag⫺/⫺ mice. This experimental system is well suited to
the analysis of complex networks of receptor–ligand interactions because disease development is synchronous and the
genotypes of the donor T cells and the immune-deficient
host can be independently varied. The most striking finding
in the work presented here was the dramatic acceleration of
colitis observed in Hvem⫺/⫺Rag⫺/⫺ mice transferred with
WT CD4+CD45RBhigh T cells. Clinical signs correlated with
an extremely fast weight loss and elevated histological scores
in the colon within 2 wk after T cell transfer. Colitis acceleration in Hvem⫺/⫺Rag⫺/⫺ recipient mice was characterized by
a rapid accumulation of activated T cells producing Th1 cytokines and IL-17 in the large intestine of these recipients.
This suggests that colitis acceleration is probably induced by
an exacerbated proinflammatory response mediated by CD4+
T cells in the large intestine.
Because of the surprising acceleration of disease in
Hvem⫺/⫺Rag⫺/⫺ mice, we performed experiments to identify
the critical cell type(s) that must express HVEM. Although
APCs were considered the most promising candidate, we
could find little evidence for a global alteration in APC function in Hvem⫺/⫺ mice, although T cells cultured in vitro
with Hvem⫺/⫺ MLN DCs and a soluble anti-CD3 mAb did
exhibit a slightly enhanced proliferative response. Surprisingly, transfer experiments using BM chimeric mice revealed
that HVEM expression on a radioresistant cell population in
the Rag⫺/⫺ animals is most critical for preventing colitis acceleration. Moreover, we found that mouse IECs expressed
high levels of HVEM. IECs are a main point of contact
for enteric antigens, and they play a direct role in regulating
T cell responses to these antigens (44). It has been recently
shown that IECs may contribute to the maintenance of T cell
tolerance in the gut by preventing inappropriate activation of
CD4+ T cells (45, 46), and they express PD-L1, the ligand for
the inhibitory receptor programmed cell death 1 (46). Nevertheless, although epithelial cell expression of HVEM is intriguing, IEC permeability was not altered in Hvem⫺/⫺ mice,
and these mice were not more susceptible to DSS colitis.
Therefore, the absence of HVEM does not alter IEC physiological function in the absence of T cell–induced inflammation, and it remains to be proven that HVEM expression by
IECs is required to prevent colitis acceleration. A radioresistant, tissue-specific APC expressing CD70, and required for
the proliferation of mucosal T cells after oral infection, was
recently identified (47), and therefore these cells or some
other radioresistant HVEM-expressing cell type could be
most responsible for preventing accelerated colitis. Conditional ablation of HVEM expression in different cell types in
Rag⫺/⫺ mice with a floxed Hvem allele ultimately will be required to identify the cell type(s) that must express this protein to prevent disease acceleration.
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During the review of this paper, it was shown in human
cells that HVEM binds to CD160, a glycophosphatidylinositol-anchored member of the Ig super family (50). The authors of this report found that the binding of CD160 by
HVEM delivered inhibitory signals to human CD4+ T cells,
leading to reduced T cell activation and cytokine production
(50). Although it is not known if this interaction takes place
in mice, we cannot rule out the possibility of an antiinflammatory role for the HVEM–CD160 interaction in the experimental colitis model. Consistent with a possible role for
CD160, when Btla⫺/⫺Rag⫺/⫺ mice were transferred with
CD4+ T cells, weight loss and histological scores were less
severe than in Hvem⫺/⫺Rag⫺/⫺ recipients. Although the differences were not statistically significant, the trend was toward milder disease in Btla⫺/⫺Rag⫺/⫺ mice. This was also
observed when Btla⫺/⫺Rag⫺/⫺ mice were transferred with
BTLA-deficient T cells, a situation where the HVEM–BTLA
interaction is completely ablated. The difference in colitis between HVEM and BTLA deficiency is not very great, however, suggesting that most of the disease-accelerating effects
of HVEM deficiency are due to interaction with BTLA as
opposed to the absence of a hypothetical interaction of mouse
HVEM with CD160.
Contrary to our expectations, the transfer of Btla⫺/⫺
CD4+CD45RBhigh T cells into Rag⫺/⫺ mice did not replicate
the severe disease phenotype in the Hvem⫺/⫺Rag⫺/⫺ recipients.
Surprisingly, we found that there was a significant reduction in
the number of T cells in different lymphoid organs and in the
large intestine after transfer of Btla⫺/⫺ CD4+ T cells. In accordance with this finding, it has recently been shown that under
conditions of chronic stimulation in a GVHD model system,
Btla⫺/⫺ T cells did not survive as well and failed to sustain
GVHD pathology (32). Therefore, decreased T cell survival
could partially explain the absence of a dramatic colitis acceleration after transfer of Btla⫺/⫺ T cells into Rag⫺/⫺ mice. It should
be noted that after transfer of Btla⫺/⫺ T cells into Rag⫺/⫺ mice,
HVEM can still induce inhibitory signals by interacting with
BTLA expressed by host cells. However, when the stromal
cells cannot deliver the critical antiinflammatory HVEM-mediated signals to either the transferred T cells or to Rag⫺/⫺ host
cells, as is the case in Hvem⫺/⫺Rag⫺/⫺ recipients, accelerated
disease occurs, even after transfer of Btla⫺/⫺ CD4+ T cells.
In summary, HVEM can act as a receptor to enhance immune responses through binding LIGHT and as a ligand to
suppress immune response by binding BTLA. It is therefore
not surprising that HVEM plays a dual role in the development of colitis. By analyzing Hvem-deficient mice and cells,
previous studies and the work presented here indicate that
the lack of HVEM expression by T cells decreased T cell activation and the development of effector functions. The effects of HVEM deficiency are cell type dependent; however,
the lack of HVEM expression by an irradiation-resistant cell
type(s) in the immune-deficient recipients caused an acceleration of intestinal inflammation. Hvem⫺/⫺ mice do not spontaneously develop colitis, however, and it is likely that in
immune-competent mice CD4+CD25+ regulatory T cells or
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Although HVEM is expressed by the transferred T cells (not
depicted), the absence of HVEM in the donor T lymphocytes
slightly reduced the severity of colitis development. Therefore,
HVEM expression by T cells apparently contributed to the enhancement of T cell effector function, opposite to the effect of
HVEM expression by cells in the RAG-deficient hosts. By
binding to the TNF family ligand LIGHT, HVEM mediates
co-stimulatory signals (11, 12, 19, 23, 24), and it was recently
shown that the severity of colitis induced by the transfer of
LIGHT-transgenic MLN cells into Rag⫺/⫺ recipients was
considerably decreased when the MLN cells were obtained
from Hvem⫺/⫺ mice (6). The authors concluded that HVEM
expression on T cells is necessary for optimal LIGHT-mediated
T cell activation and expansion in this system (6). Therefore, T
cell–derived LIGHT interacting with HVEM expressed by the
same or an adjacent T cell may be required for the full Th1
and/or Th17 differentiation of gut-homing effector T cells (4).
Evidence suggesting a potential for T–T interactions between
LIGHT and HVEM on donor T cells also has been developed in
a GVHD model system (48). Consistent with the co-stimulatory
role of LIGHT, we found that mice transferred with Light⫺/⫺
CD4+CD45RBhigh T cells also had lower histological scores. It is
noteworthy that if the effect of HVEM deficiency in the RAGdeficient host were mediated predominantly by interactions with
T cell–expressed LIGHT, colitis should have been accelerated,
rather than delayed, after transfer of Light⫺/⫺ CD4+CD45RBhigh
T cells. When either Light⫺/⫺ or Hvem⫺/⫺ CD4+CD45RBhigh T
cells were transferred into Hvem⫺/⫺Rag⫺/⫺ animals, however,
the disease-accelerating effects of the absence of HVEM in
the Rag⫺/⫺ host were dominant over the more subtle diseasedelaying effects when these molecules were not expressed by the
gene-deficient donor T cells. Therefore, the predominant effect
of HVEM in this colitis model system is antiinflammatory, and it
is related to its expression by radiation-resistant innate cells in the
Rag⫺/⫺ hosts.
Because BTLA is an inhibitory receptor for T cells, it was
a good candidate for mediating the antiinflammatory effect of
HVEM expression in the Rag⫺/⫺ recipients. Consistent with
this hypothesis, treatment of Hvem⫺/⫺Rag⫺/⫺ recipients of
CD4+CD45RBhigh T cells with an anti-BTLA mAb with agonistic properties was able to reverse the accelerated colitis, but
only when the T cells expressed BTLA. Although our data
clearly demonstrate that a major function of the anti-BTLA
mAb is to attenuate T cell responses, BTLA expression by host
cells is also relevant. The transfer of WT T cells into BTLAdeficient Rag⫺/⫺ recipients also led to accelerated colitis, indicating that T cell expression of BTLA is necessary but not
sufficient, and that there also is a function for BTLA expression
by host cells in preventing colitis acceleration. BTLA expression has been detected on myeloid and lymphoid cells, including CD11c+ DCs, a subpopulation of CD11b+ macrophages
and also DX5+ NK cells (27, 42). Interestingly, NK cells have
been shown to prevent accelerated colitis development in the
T cell transfer model of colitis (49). Therefore, engagement of
BTLA on one or more of these innate immune cell types could
contribute to moderating colitis progression.

Published June 2, 2008

MATERIALS AND METHODS
Mice. C57BL/6, Rag⫺/⫺ (C57BL/6 background), and C57BL/6-SJL
CD45.1 congenic mice were purchased from The Jackson Laboratory and
maintained in our facility. Btla⫺/⫺ (28), Light⫺/⫺ (37), and Hvem⫺/⫺ mice
(26) have been described previously. All gene-deficient mice were backcrossed for at least six generations onto the C57BL/6 background. Hvem⫺/⫺ or
Btla⫺/⫺ mice were crossed to Rag⫺/⫺ mice to generate Hvem⫺/⫺Rag⫺/⫺ and
Btla⫺/⫺Rag⫺/⫺ recipient animals, respectively. Mice were maintained at the
La Jolla Institute for Allergy and Immunology under specific pathogen-free
conditions, and sentinels from the mouse colony tested negative by PCR
detection of Helicobacter spp. and Citrobacter rodentium. Mice were used at
7–12 wk of age. Animal care and experimentation were consistent with the
National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committee at the La Jolla Institute for Allergy
and Immunology.
Antibodies and reagents. The following mouse antibodies were purchased from BD Biosciences as conjugated to FITC, PE, PE-Cy5, PerCPCy5.5, or allophycocyanin: CD4 (L3T4), CD45RB (16A), CD45.2
(104), TCR ␤ chain (H57-597), and rat anti–hamster IgG (cocktail).
A PE-conjugated and purified anti – mouse BTLA mAb (6F7) were
purchased from eBioscience and Bio Express, Inc., respectively. Anti–
mouse HVEM antibody (26) was provided by Y.X. Fu (University of
Chicago, Chicago, IL). Anti–mouse CD16/32 used for Fc receptor blocking was purified in our laboratory. Purified mouse IgG1 was purchased
from Millipore.
CD4+ CD45RBhigh T cell isolation and transfers. Spleens were removed from the donor mice (C57BL/6, Light⫺/⫺, Hvem⫺/⫺, Btla⫺/⫺, or B6SJL CD45 congenic) and teased into cell-single suspensions in HBSS media
(Invitrogen). Cell suspensions were filtered through a 70-μm cell strainer
(Thermo Fisher Scientific), and then CD4+ cells were enriched by positive
selection using anti-CD4 (L3T4) microbeads according to the manufacturer’s protocol (Miltenyi Biotec). The CD4+-enriched cells were washed
twice and stained with PE-Cy5–conjugated anti-CD4 and PE-conjugated
anti-CD45RB antibodies. After staining, the cells were washed, and the
CD4+CD45RBhigh T cell population was sorted by flow cytometry using a
FACS-DIVA cell sorter (Becton Dickinson). Purified CD4+CD45RBhigh
naive T cells were washed twice and resuspended in PBS, and 5 × 105 cells
in 200 μl of PBS were injected i.v. into the different recipient mice. Trans1474

ferred mice were monitored regularly for signs of disease, including weight
loss, hunched over appearance, piloerection of the coat, and diarrhea. For
cotransfer experiments, CD4+CD45RBhigh T cells were isolated from congenic CD45.1+ and CD45.2+ Btla⫺/⫺ mice, mixed in equal numbers and injected i.v. into Rag⫺/⫺ recipients.
Preparation of IELs and LPLs. Mucosal lymphocytes were isolated and
prepared as described previously (34). In brief, the large intestine was removed and placed in chilled HBSS media containing 5% FCS. The intestines
were carefully cleaned from their mesenteries and flushed of fecal content.
Intestines were opened longitudinally and cut into 1-cm pieces. The intestinal tissue was transferred to 250-ml Erlenmeyer flasks containing 25 ml of
preheated HBSS supplemented with 2% FBS and 1 mM DTT (SigmaAldrich) and shaken at 200 rpm for 40 min at 37°C. The tissue suspensions
were passed through a stainless steal sieve into 50-ml conical tubes, and the
cells were pelleted by centrifugation at 1,200 rpm for 10 min at 4°C. The
cell pellets were resuspended in complete HBSS, layered over a discontinuous 40/70% Percoll (GE Healthcare) gradient, and centrifuged at 2,000 rpm
for 30 min. Cells from the 40/70% interface were collected, washed, and resuspended in complete RPMI media (Invitrogen). These purified cells constituted the IEL population. To isolate LPLs, the remaining intestinal tissue
in the stainless steal sieve was minced and transferred to conical tubes. The
minced pieces were resuspended in 20 ml of complete RPMI containing
1 mg/ml of type IV collagenase (Sigma-Aldrich) and shaken at 200 rpm for
40 min at 37°C. The tissue suspension was collected and passed through a
70-μm cell strainer, and then the cells were pelleted by centrifugation at
1,200 rpm. The cells were then resuspended and layered onto a 40/70%
Percoll gradient, centrifuged, and processed as described above for the
IEL preparation.
Histology. At various time points after cell transfer, animals were killed for
histological analysis. Tissue samples of 3–5 mm obtained from distal and
proximal portions of the large intestine were fixed in 4% formalin. Fixed tissues were later embedded in paraffin and 3-μm sections were prepared and
stained with H&E. To evaluate the severity of the inflammation, samples
were coded and scored by a pathologist in a blinded fashion using a previously described scoring system (34). Scores from the two parts of the intestine were averaged to represent the severity of disease. Higher scores
(maximum 14) indicate greater pathology. Categories scored are the following: degree of inflammatory cell infiltrate in the lamina propria, goblet cell
depletion, epithelial cell reactive atypia/hyperplasia, number of IELs in epithelial crypts, and number of inflammatory foci.
Flow cytometry analysis. Spleens and MLNs were removed and then
mashed through a 70-μm cell strainer, and red blood cells in the cell suspension were removed using a lysing buffer (Sigma-Aldrich). IELs and LPLs
were isolated as described above. Before staining, cells were washed and resuspended in staining buffer containing 1× PBS, 2% BSA, 10 mM EDTA,
and 0.01 NaN3. To block nonspecific staining, anti-CD16/32 antibody
was added. Antibodies for cell surface markers were added, and cells were
incubated for 20 min on ice. After staining, the cells were washed twice
with staining buffer, analyzed the same day or fixed in PBS containing
1% paraformaldehyde and 0.01 NaN3, and analyzed later in a FACSCalibur
(BD Biosciences).
Detection of cytokines by ELISA. 2 wk after the transfer of
CD4+CD45RBhigh T cells, LPLs were isolated from the recipients and 106
cells were cultured in RPMI complete medium in the presence of PMA and
ionomycin for 48 h. The amounts of IFN-␥, IL-4, TNF, and IL-2 in the
culture supernatants were quantified by ELISA. Antibodies and recombinant
cytokine standards were purchased from BD Biosciences.
RNA isolation and real-time PCR. 2 wk after the transfer of
CD4+CD45RBhigh T cells, 1.5 cm from the large intestines of the recipients
was removed and resuspended in TRIZol (Invitrogen). The samples were
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other mechanisms prevent gut inflammation. Moreover, the
counterbalancing effects of HVEM expression by different
cell types, and the dual engagement of proinflammatory
LIGHT and antiinflammatory BTLA by HVEM, may explain the absence of spontaneous colitis in Hvem⫺/⫺ mice.
Our findings therefore depended critically on the power of
the T cell transfer model of colitis in analyzing cell–cell interactions and the interplay of the innate adaptive immune systems,
as we could separate the proinflammatory and antiinflammatory effects of HVEM expression by comparing Hvem⫺/⫺ T cell
donors and Hvem⫺/⫺Rag⫺/⫺ recipients to their WT counterparts. Although the majority of studies on HVEM have addressed the participation of this molecule when expressed by
T cells or APCs, our studies demonstrate the unexpected and
important role that this molecule plays to prevent inflammation
when expressed by irradiation-resistant nonlymphoid cells.
The expression of HVEM and BTLA on both innate and
adaptive cells, along with the findings presented here, suggest
that this ligand–receptor system could play diverse roles in
immunity and inflammation in both the innate and adaptive
immune systems that have yet to be fully elucidated.
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Generation of BM chimeras. Rag⫺/⫺ or Hvem⫺/⫺Rag⫺/⫺ hosts were
lethally irradiated with 11 Gy that were applied in two irradiations of 5.5 Gy
separated by a 3-h interval. After irradiation, Hvem⫺/⫺Rag⫺/⫺ hosts were transplanted with 5 × 106 total BM cells isolated from Rag⫺/⫺ mice to generate
Rag⫺/⫺→Hvem⫺/⫺Rag⫺/⫺ chimeric animals. Reciprocal Hvem⫺/⫺Rag⫺/⫺→
Rag⫺/⫺ chimeras were generated by transplanting Hvem⫺/⫺Rag⫺/⫺ BM cells
into irradiated Rag⫺/⫺ hosts. After transplant, mice were maintained under antibiotic treatment for 4 wk and an additional 6 wk without antibiotic before
transfer of the CD4+CD45RBhigh T cells.
Statistics. Differences between groups were evaluated for statistical significance by the two-tailed unpaired Student’s t test, except for histological
scoring that was evaluated using Wilcoxon’s two-group test. Results are expressed as mean ± SD. p-values of <0.05 were considered significant.
Online supplemental material. Fig. S1 (A and B) shows, respectively, the
phenotype of freshly isolated or LPS-stimulated CD11c+ cells isolated from
the MLNs of WT or Hvem⫺/⫺ mice. Fig. S1 C shows proliferation assessed
by CFSE dilution of CD4+CD25⫺ T cells cultured with WT or Hvem⫺/⫺
CD11c+ and an anti-CD3 mAb. Fig. S2 A shows HVEM expression on
purified primary colonic epithelial cells. Fig. S2 B shows the results from intestinal permeability experiments performed on distal colons isolated from
untreated WT and Hvem⫺/⫺ mice or WT animals treated with 4% DSS. Fig.
S3 (A and B) shows, respectively, weight loss curves and histological scores
of WT and Hvem⫺/⫺ mice treated with 2.5% DSS. Fig. S4 (A–D) shows the
effect of an anti-BTLA mAb (6F7) on T cell activation, in particular CD25
expression and IL-2 production. The online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20071160/DC1.
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then frozen at ⫺80°C. For RNA isolation, the whole tissue was homogenized, DNA and proteins were removed by precipitation with chloroform,
and RNA was extracted with isopropanol. cDNA was synthesized from the
total RNA using the Superscript II system (Invitrogen) according to the
manufacturer’s instructions. Subsequently, the cDNA was subject to realtime PCR using SYBR green (Bio-Rad Laboratories) and the following
mouse primers: TNF forward, 5⬘-CATCTTCTCAAAATTCGAGTGACAA-3⬘; TNF reverse, 5⬘-TGGGAGTAGACAAGGTACAACCC-3⬘;
IFN-␥ forward, 5⬘-TCAAGTGGCATAGATGTGGAAGAA-3⬘; IFN-␥
reverse, 5⬘-TGGCTCTGCAGGATTTTCATG-3⬘; IL-4 forward, 5⬘ACAGGAGAAGGGACGCCAT-3⬘; IL-4 reverse, 5⬘-GAAGCCCTACAGACGAGCTCA-3⬘; IL-17 forward, 5⬘-GGTCAACCTCAAAGTCTTTAACTC-3⬘; IL-17 reverse, 5⬘-TTAAAAATGCAAGTAAGTTTGCTG3⬘; IL-12p35 forward, 5⬘-TGAAGACGGCCAGAGAAAAAC-3⬘; IL-12p35
reverse, 5⬘-AAGGAACCCTTAGAGTGCTTACT-3⬘; IL-23p19 forward,
5⬘-AGCGGGACATATGAATCTACTAAGAGA-3⬘; IL-23p19 reverse,
5⬘-GTCCTAGTAGGGAGGTGTGAAGTTG-3⬘; IL-10 forward, 5⬘GGTTGCCAAGCCTTATCGGA-3⬘; IL-10 reverse, 5⬘-ACCTGCTCCACTGCCTTGCT-3⬘; TGF-␤ forward, 5⬘-TGACGTCACTGGAGTTGTACGG-3⬘; TGF-␤ reverse, 5⬘-GGTTCATGTCATGGATGGTGC-3⬘;
L32 forward, 5⬘-GAAACTGGCGGAAACCCA-3⬘; and L32 reverse,
5⬘-GGATCTGGCCCTTGAACCTT-3⬘. Gene expression was normalized to
L32. Data were collected and analyzed on an iCycler (Bio-Rad Laboratories).
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